‘Every clinician is aware of the issues and problems associated with drug – eluting stents and the increased risk of late and very late stent thrombosis, , inflammatory, inflammatory or hypersensitivity reactions as well as the economic impact of maintaining long-term dual antiplatelet therapy, ‘said Corrado Tamburino, FSICI-GISE, Professor of Cardiology and Director of the Cardiovascular Department, Ferrarotto Hospital, Catania, Italy, and principal investigator of the ATLANTA Trial. ‘the 12-month ATLANTA data indicate that the CATANIA stent with PolyZen F is truly a new and promising class of stent. Further, the CATANIA stent may safety profile safety profile as demonstrated that there that it.
We have the CATANIA stent proved to be highly available, flexible and trackable even in tortuous anatomy, said Dr. Tamburino. The PolyZen F surface treatment gives the stent with exceptional qualities that inspired not only a highly lubricious, user confidence and improved pushability, but also hides the stent from the body’s defenses, of the polymer. The potential reduction of thrombosis. .
The rapid exchange leads cobalt chromium CATANIA stent is CE marked and is currently available for sale outside the United States in 60 sizes, in lengths from 8 – 38mm and in diameters of 2, ‘The CATANIA stent is the next evolution in angioplasty treatment, ‘ President and Chief Executive Officer, CeloNova Biosciences, ‘doctors, health systems and insurance programs need breakthroughs, not what is already marginally better than what already exists marginal improvements prior competition;. Continue reading